Psilera closes oversubscribed $8.8M seed extension to advance PSIL-006 into first-in-human trials
What's the deal? Psilera, a Tampa-based biopharmaceutical startup developing next-generation neuroplastogens, has closed an oversubscribed $8.8M seed extension round. The company plans to use the capital to advance its lead compound, PSIL-006, into first-in-human trials in 2027.
PSIL-006 is designed to deliver the therapeutic benefits of traditional psychedelic compounds — think neuroplasticity and mood improvement — while minimising hallucinogenic effects and cardiovascular risks. A syndicate of institutional and strategic investors backed the round.
Why now? The funding comes on the heels of several milestones. Psilera appointed neuroscience industry veteran Magali Haas as chief medical officer, secured an NIH award of up to $2M for studies of PSIL-006 in alcohol use disorder, and signed a licensing deal with AtaiBeckley for its DMT patent portfolio.
There's also a regulatory tailwind. A recent US executive order titled "Accelerating Medical Treatments for Serious Mental Illness" aims to increase access to psychedelic drugs and speed up development of novel treatments. Psilera chief executive officer Chris Witowski said the company looks forward to working with regulators "to fully develop PSIL-006."
What could go wrong? Drug development is inherently risky — most compounds fail before reaching patients. PSIL-006 still faces IND-enabling studies and the unpredictable hurdles of clinical trials. The broader psychedelic medicine space has also seen setbacks: the FDA rejected MDMA-assisted therapy for PTSD in 2024, underscoring how high the bar remains for novel neuropsychiatric treatments.
Psilera is also still early-stage. An $8.8M seed extension may fund the path to first-in-human trials, but the company will likely need significantly more capital to complete clinical development.
The signal: Psilera's oversubscribed round underscores persistent investor conviction in the "non-hallucinogenic psychedelic" thesis, even as the broader space navigates setbacks like the FDA's 2024 rejection of MDMA-assisted therapy. Classified as early growth on Dealroom, the company's pivot from discovery-stage to clinical-stage organisation — backed by NIH funding and a strategic licensing deal with AtaiBeckley — suggests it is building the kind of de-risked asset pipeline that institutional investors increasingly demand before committing capital in this sector.
Read more: Benzinga
